Cargando…
A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
Oncogenic K-RAS mutations are found in virtually all pancreatic cancers, making K-RAS one of the most targeted oncoproteins for drug development in cancer therapies. Despite intense research efforts over the past three decades, oncogenic K-RAS has remained largely “undruggable”. Rather than targetin...
Autores principales: | Van Sciver, Robert E., Lee, Michael P., Lee, Caroline Dasom, Lafever, Alex C., Svyatova, Elizaveta, Kanda, Kevin, Collier, Amber L., Siewertsz van Reesema, Lauren L., Tang-Tan, Angela M., Zheleva, Vasilena, Bwayi, Monicah N., Bian, Minglei, Schmidt, Rebecca L., Matrisian, Lynn M., Petersen, Gloria M., Tang, Amy H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5977115/ https://www.ncbi.nlm.nih.gov/pubmed/29757973 http://dx.doi.org/10.3390/cancers10050142 |
Ejemplares similares
-
Perspectives on Triple-Negative Breast Cancer: Current Treatment Strategies, Unmet Needs, and Potential Targets for Future Therapies
por: Gupta, Gagan K., et al.
Publicado: (2020) -
SIAH and EGFR, Two RAS Pathway Biomarkers, are Highly Prognostic in Locally Advanced and Metastatic Breast Cancer
por: van Reesema, Lauren L. Siewertsz, et al.
Publicado: (2016) -
Drugging the Undruggable: Advances on RAS Targeting in Cancer
por: Molina-Arcas, Miriam, et al.
Publicado: (2021) -
Targeting the “undruggable” RAS - new strategies - new hope?
por: Mörchen, Britta, et al.
Publicado: (2019) -
Drugging an undruggable pocket on KRAS
por: Kessler, Dirk, et al.
Publicado: (2019)